Kaplan-Meier comparison of overall survival between patients at MDACC in study INCB18424-251 and the historical control population. (A) Kaplan-Meier plot of overall survival for ruxolitinib-treated and historical control patients, with HR, 95% CI, and P value, adjusted for baseline IPSS risk status. There were 33 deaths in the ruxolitinib-treated group (N = 107) and 187 deaths in the control group (N = 310). (B) Kaplan-Meier plot of overall survival for ruxolitinib-treated and historical control patients designated as high risk according to the IPSS. There were 21 deaths in the high-risk ruxolitinib-treated group (N = 63) and 111 deaths in the control group (N = 165). (C) Kaplan-Meier plot of overall survival for ruxolitinib-treated and historical control patients designated as intermediate-2 according to the IPSS. There were 10 deaths in the intermediate-2 risk ruxolitinib-treated group (N = 34) and 76 deaths in the control group (N = 145). (D) Kaplan-Meier plot of overall survival for ruxolitinib-treated patients at MDACC in study INCB18424-251 designated as high risk and intermediate-2 according to the IPSS. *Hazard ratio >1 favors intermediate-2 risk group.